BioBlast Pharma (ORPN) Tops Q3 EPS by 4c

BioBlast Pharma (NASDAQ: ORPN) reported Q3 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29).

BioBlast ended the third quarter of 2015 with $23.1 million in cash and short-term bank deposits, total quarterly expenses were $3.6 million whereas total quarterly expenses excluding stock based compensation were $3.0 million.

On November 16, 2015, the Company announced the appointment of three new senior executives to its leadership team: Warren Wasiewski, M.D. as Chief Medical Officer and Vice President, Research & Development, Leigh Cherry as Vice President Manufacturing, and Stacey Jurchison as Vice President, Investor Relations & Corporate Communications. All are U.S.-based positions with global responsibilities. This is consistent with our objective of significantly enhancing our global reach and specifically, U.S. presence.

For earnings history and earnings-related data on BioBlast Pharma (ORPN) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold